You wake up one morning and your back gives out. Or your knee, which has been quietly complaining for weeks, finally stops cooperating. You’re in pain, you’re not sure what’s wrong, and you need help.
What happens next depends almost entirely on where you start.
For millions of Americans dealing with musculoskeletal pain every year, that first decision sets off a cascade of referrals, imaging orders, specialist appointments, and in too many cases, procedures that could have been avoided entirely. The wrong entry point into the healthcare system doesn’tjust delay recovery. It drives costs that compound for months afterward.
For Airrosti patients, that cascade looks fundamentally different. And now, an independent analysis conducted by Optum Advisory shows just how different.
The Study: Built to Hold Up to Scrutiny
Airrosti partnered with Optum, one of the most respected names in healthcare analytics, to answer a simple question:
Do Airrosti patients experience different cost outcomes than similar patients treated elsewhere?
Optum designed the methodology, ran the analysis, and delivered the findings.
Using propensity score matching, a gold-standard approach in outcomes research, Optum built a control group of patients who looked nearly identical to Airrosti patients on paper: same age range, same gender, same health conditions, similar prior healthcare spend. The only meaningful difference was that one group was treated by Airrosti and the other wasn’t.
They then tracked what happened to both groups over the following 12 months across inpatient, outpatient, emergency, surgical, pharmacy, and professional services.
The findings carried a p-value of less than 0.0001, meaning the probability these results occurred by chance is vanishingly small.
This wasn’t a survey. It wasn’t self-reported data.
It was a rigorous, independent analysis of real claims data.
The result: Airrosti care and clinical judgment generated $3,607 less in total healthcare costs per member per year than the matched control group.
Why the Cost Picture Looks so Different:
Most MSK care follows a predictable, expensive script. A patient shows up in pain. They get a referral. Then imaging. Then a specialist. Then, too often, a surgical consult for a problem that could have been resolved much earlier if someone had treated it directly at the point of first contact.
Airrosti changes the starting point.
Providers spend up to an hour assessing and treating the root cause of pain at the first visit. Patients leave with a clear plan and begin recovery immediately, not weeks later.
When that happens, the downstream events don’t occur.
No unnecessary imaging.
No avoidable ER visits.
No prolonged cycles of trial and error.
When that model works, the downstream costs simply don’t accumulate the same way. A patient who gets better in a handful of visits doesn’t end up in an outpatient surgical center. A patient who has a provider resolving their pain directly doesn’t show up in the ER when it flares. The $3,607 gap is the absence of a costly chain of events that never needed to start.
We’ll break down the specific cost categories in the next post in this series. The full study goes even deeper.
Why This Matters for Payers and Employers
Musculoskeletal cost reduction has become a top priority because MSK conditions are the single largest driver of healthcare costs for most self-funded employers and health plans. Chronic back pain, joint injuries, and musculoskeletal disorders collectively cost the U.S. healthcare system hundreds of billions of dollars annually, and a significant portion of that spend is concentrated in exactly the categories where Airrosti is producing savings.
The Optum study offers something that has been genuinely difficult to find in the MSK space: independent, actuarially rigorous evidence that a different approach to care produces meaningfully different financial outcomes. The kind of evidence that holds up in a benefits committee meeting or a conversation with a CFO who wants to know where the MSK budget is actually going.
The implications extend beyond cost. Lower surgical rates mean less time away from work. Fewer ER visits mean members are accessing care through the right channel. Faster resolution means higher satisfaction and less chronic pain carried into the following plan year.
The full Optum MSK Cost Savings Study is available now. Download it to see the complete methodology, the category-by-category breakdown, and what these findings mean for your organization.
